EPITRANSCRIPTOMICS IN CANCER PROGRESSION πŸŽ—️

“β„‚π•π• π•Ÿπ•’π• 𝕖𝕧𝕠𝕝𝕦π•₯π•šπ• π•Ÿ π•šπ•€ π•₯𝕙𝕖 π•–π•Ÿπ•˜π•šπ•Ÿπ•– 𝕠𝕗 π•”π•’π•Ÿπ•”π•–π•£ π•‘π•£π• π•˜π•£π•–π•€π•€π•šπ• π•Ÿ; π•₯𝕙𝕖 π•₯π•¦π•žπ• π•£ π•šπ•€ π•Ÿπ• π•₯ π• π•Ÿπ•– π•–π•Ÿπ•₯π•šπ•₯π•ͺ 𝕓𝕦π•₯ 𝕒 𝕑𝕠𝕑𝕦𝕝𝕒π•₯π•šπ• π•Ÿ 𝕠𝕗 π•”π• π•žπ•‘π•–π•₯π•šπ•Ÿπ•˜ π•”π•π• π•Ÿπ•–π•€.” - Professor Peter Nowell (Emeritus)

🧬 Cancer remains a leading cause of morbidity & mortality worldwide, characterized by uncontrolled cell growth, invasion, and metastasis. Beyond genetic alterations, post-transcriptional regulation of RNA has emerged as a critical determinant of cancer biology. Epitranscriptomics, the study of chemical modifications on RNA, provides a dynamic layer of regulation influencing RNA stability, translation, & cellular localization.

πŸ”Ή Epitranscriptomic modifications include N6-methyladenosine (m6A), 5-methylcytidine (m5C), pseudouridine (Ξ¨), and RNA editing. These modifications are catalyzed by "writers" (e.g., methyltransferases), recognized by "readers," & reversed by "erasers" (demethylases), allowing fine-tuned responses to physiological and stress signals.

πŸ”Ή Among these, m6A is the most prevalent in eukaryotic mRNA & profoundly impacts cancer progression. Overexpression of the m6A writer METTL3 promotes tumor proliferation & poor prognosis, while reduced activity of demethylases like FTO is linked to malignancy progression. m6A modulates oncogene and tumor suppressor expression by affecting mRNA stability & translation, establishing a pro-tumorigenic environment.

πŸ”Ή Other modifications also contribute: m5C, mediated by NSUN2, supports aggressive phenotypes in cancers like glioblastoma. Pseudouridine stabilizes RNAs under stress, facilitating cancer cell survival. Collectively, these modifications demonstrate the broad epitranscriptomic regulation of tumor biology.

➡️ The tumor microenvironment (TME) shapes cancer progression and therapy response. RNA modifications influence cancer stroma interactions, including immune cell recruitment. For instance, m6A affects cytokine & chemokine expression, driving immune evasion or pro-tumor inflammation. Moreover, hypoxia; a common TME feature, modulates RNA modification machinery, enhancing tumor adaptation & therapy resistance.

➡️ Targeting RNA-modifying enzymes represents a promising strategy. Small molecules that inhibit m6A demethylases or enhance methyltransferase activity could suppress tumor growth. The reversibility of RNA modifications offers an advantage over permanent genetic alterations, enabling dynamic, precision-based interventions tailored to individual epitranscriptomic profiles.

⚠️ In an Oystershell, epitranscriptomics is a frontier in cancer research, revealing how RNA modifications, especially m6A, m5C, and pseudouridine, influence tumor behavior & TME interactions.

Abubakar Abubakar ✍🏻

• He, L., et al. (2019). Molecular Cancer, 18(1), 176.

• Shi et al, (2019). Molecular Cell, 74(4), 640-650.

#Epitranscriptomics #m6A #RNAmodifications #RNAResearch #TargetedTherapy #CRISPR #NGS ⚕️

Popular posts from this blog

GENE DUPLICATIONS IN EVOLUTIONARY INNOVATION

Image
"π”Ύπ•–π•Ÿπ•– π••π•¦π•‘π•π•šπ•”π•’π•₯π•šπ• π•Ÿ π•‘π•£π• π•§π•šπ••π•–π•€ 𝕒 π•£π•–π••π•¦π•Ÿπ••π•’π•Ÿπ•”π•ͺ π•₯𝕙𝕒π•₯ 𝕗𝕣𝕖𝕖𝕀 π• π•Ÿπ•– 𝕔𝕠𝕑π•ͺ π•—π•£π• π•ž 𝕀𝕖𝕝𝕖𝕔π•₯π•šπ•§π•– π•”π• π•Ÿπ•€π•₯π•£π•’π•šπ•Ÿπ•₯, π•’π•π•π• π•¨π•šπ•Ÿπ•˜ π•šπ•₯ π•₯𝕠 𝕖𝕩𝕑𝕝𝕠𝕣𝕖 π•Ÿπ•–π•¨ π•—π•¦π•Ÿπ•”π•₯π•šπ• π•Ÿπ•’π• 𝕀𝕑𝕒𝕔𝕖." - Dr. Richard Lewontin 🧬 Gene duplications are a driving force in evolution, offering raw material for innovation. They arise through mechanisms like unequal crossing over, retroposition, or whole-genome duplication (WGD). Once a gene is duplicated, one copy can conserve its original role, while the other diverges; fueling new functions, adaptations, or even nonfunctionalization (pseudogenes).           πŸ”Ή The evolutionary fates of gene duplications includes: Subfunctionalization: split ancestral functions across duplicates. Neofunctionalization: gain of new roles, which is vital for innovation. Pseudogenization: loss of function. A classic case is the globin gene family: duplications enabled the evolution of h...
Read more

MUTATIONAL SIGNATURES IN CANCER GENOMES πŸŽ—️

Image
“𝕋𝕙𝕖 π•˜π•–π•Ÿπ• π•žπ•– 𝕠𝕗 𝕖𝕧𝕖𝕣π•ͺ π•”π•’π•Ÿπ•”π•–π•£ π•‘π•£π• π•§π•šπ••π•–π•€ 𝕒 π•œπ•šπ•Ÿπ•• 𝕠𝕗 ‘π•’π•£π•”π•™π•’π•–π• π•π• π•˜π•šπ•”π•’π• 𝕣𝕖𝕔𝕠𝕣𝕕,’ π•¨π•£π•šπ•₯π•₯π•–π•Ÿ π•šπ•Ÿ π•₯𝕙𝕖 𝔻ℕ𝔸 𝕔𝕠𝕕𝕖 π•šπ•₯𝕀𝕖𝕝𝕗, 𝕠𝕗 π•₯𝕙𝕖 𝕖𝕩𝕑𝕠𝕀𝕦𝕣𝕖𝕀 π•₯𝕙𝕒π•₯ 𝕔𝕒𝕦𝕀𝕖𝕕 π•₯𝕙𝕖 π•žπ•¦π•₯𝕒π•₯π•šπ• π•Ÿπ•€ π•₯𝕙𝕒π•₯ 𝕝𝕖𝕒𝕕 π•₯𝕠 π•₯𝕙𝕖 π•”π•’π•Ÿπ•”π•–π•£.” - Sir. Mike Stratton 🧬 Cancer arises from the accumulation of somatic mutations, each carrying clues about the biological and environmental forces that shaped the tumor’s evolution. With the advent of high-throughput sequencing and large-scale projects like TCGA and ICGC, we have uncovered distinct mutational signatures; recurring patterns of DNA alterations that reflect specific mutagenic processes. πŸ”Ή What are mutational signatures? They are characteristic patterns of nucleotide substitutions, insertions, or deletions, shaped by mechanisms such as aging, tobacco exposure, UV light, or defective DNA repair. For example, Signature 1 correlates with age-related deamin...
Read more